WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124665
CAS#: N/A
Description: Anaprazole is a novel proton pump inhibitor under development for the treatment of gastric and duodenal ulcers.
Hodoodo Cat#: H124665
Name: Anaprazole
CAS#: N/A
Chemical Formula: C21H24N2O4S
Exact Mass: 400.15
Molecular Weight: 400.490
Elemental Analysis: C, 62.98; H, 6.04; N, 6.99; O, 15.98; S, 8.01
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ANAPRAZOLE; W6OO9ZB0FC; CHEMBL4651083
IUPAC/Chemical Name: 2-((3-(3-methoxypropoxy)-2-methylbenzyl)sulfinyl)-6,7-dihydro-1H-benzofuro[5,6-d]imidazole
InChi Key: JYSIFLQJDVIWKM-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H24N2O4S/c1-14-16(5-3-6-19(14)26-9-4-8-25-2)13-28(24)21-22-17-11-15-7-10-27-20(15)12-18(17)23-21/h3,5-6,11-12H,4,7-10,13H2,1-2H3,(H,22,23)
SMILES Code: CC1=C(C=CC=C1OCCCOC)CS(=O)C2=NC3=C(N2)C=C4CCOC4=C3
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 400.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Tang C, Li L, Ma X, Wang J, Chen B, Dai X, Zhang Y, Chen X. Qualitative and
quantitative determination of anaprazole and its major metabolites in human
plasma. J Pharm Biomed Anal. 2020 May 10;183:113146. doi:
10.1016/j.jpba.2020.113146. Epub 2020 Feb 4. PMID: 32086126.
2: Shu X, Zhu Z, Fu Y, Zhang Z, Wang J, Li X, He S, Fan H, Liu S, Zhang G, Tang
J, Huang C, Du Q, Wang X, Xu B, Du Y, Chen Q, Wang B, Chen Y, Duan X, Xie Y, Huo
L, Hou X, Lu N. Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel
PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-
Blinded Multicenter Phase II Clinical Trial. Front Med (Lausanne). 2021 Jul
14;8:690995. doi: 10.3389/fmed.2021.690995. PMID: 34336894; PMCID: PMC8317206.
3: Zhu H, Pan X, Zhang L, Sun H, Fan H, Pan Z, Huang C, Shi Z, Ding J, Wang Q,
Du Y, Lyu N, Li Z. Effect and safety of anaprazole in the treatment of duodenal
ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Chin Med J (Engl). 2022 Dec 20;135(24):2941-2949. doi:
10.1097/CM9.0000000000002508. PMID: 36580650; PMCID: PMC10106214.
4: Ding S, Xie L, Wang L, Zhou C, Zhou S, Chen J, Zhu B, Liu Y, Zhu J, Zhang Z,
Li T, Wang L, Zhang Z, Shao F. Pharmacokinetic Interaction of Anaprazole,
Amoxicillin and Clarithromycin after Single-Dose Simultaneous Administration and
the Effect of Adding Bismuth on Their Pharmacokinetics in Healthy Male Chinese
Subjects. Eur J Drug Metab Pharmacokinet. 2023 Mar;48(2):121-132. doi:
10.1007/s13318-022-00810-8. Epub 2022 Dec 15. PMID: 36520316.
5: Liu F, Xu Y, Wang L, Ma X, Zhang Z, Zhuang X. Combined contributions of
cytochrome P450s (CYPs) and non-enzymatic metabolism in the in vitro
biotransformation of anaprazole, a novel proton pump inhibitor. Naunyn
Schmiedebergs Arch Pharmacol. 2023 Aug;396(8):1759-1771. doi:
10.1007/s00210-023-02415-7. Epub 2023 Feb 27. PMID: 36847804.